Atlas Trials

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

Clinical trial NCT06081777 · UNKNOWN

Trial details

NCT number
NCT06081777
Sponsor
Peking University Cancer Hospital & Institute
Status
UNKNOWN
Study type
OBSERVATIONAL
NSCLC
Start date
2022-11-25
Primary completion
2025-06-01
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.